Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."| CNBC
Trump on Tuesday said his administration will be announcing a "major" tariff on pharmaceuticals "very shortly."| CNBC
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.| CNBC
The burgeoning weight-loss drug industry could be worth as much as $200 billion within the next decade, according to Barclays bank.| CNBC
